Why a wonky health policy debate has become a national issue
In South Korea, a country better known to many Americans for K-pop, Oscar-winning films and some of the world’s fastest internet, one of the most urgent national debates this spring is about something far less glamorous: how quickly the government should help patients get access to drugs for rare diseases.
At the center of the discussion is a proposal often described as a “100-day listing” system — a plan to dramatically speed up the process for adding rare disease treatments to the national health insurance system. In practical terms, that would mean shortening the time between a drug becoming available and patients actually being able to afford it under Korea’s single-payer-style public insurance structure.
That may sound technical, but for families dealing with severe genetic disorders, pediatric neurological conditions or rapidly progressive metabolic diseases, the policy question is brutally simple: How many months can a patient afford to wait?
Under the system now being debated for 2026 health policy planning, South Korean officials are considering not only a faster insurance pathway for rare disease drugs, but also a broader expansion of state responsibility. One idea gaining attention would allow the government to directly procure certain medicines from overseas — including drugs that families have sometimes had to obtain on their own through so-called “direct purchase” channels, a cumbersome and risky workaround that can involve foreign pharmacies, customs issues, cold-chain storage concerns and lingering fears about authenticity and supply interruptions.
The debate marks a potentially important shift in how South Korea thinks about medicine access. Rather than treating each high-cost rare disease drug as a one-off controversy, policymakers are increasingly asking whether the state should build a standing public safety net for medicines that are essential, difficult to replace and often out of reach through normal market channels.
For American readers, the closest comparison may be the recurring U.S. fights over access to gene therapies, orphan drugs and other highly specialized treatments that can cost hundreds of thousands or even millions of dollars. But Korea’s system adds a different twist: Because the country has universal national health insurance, the issue is not simply whether a patient has coverage. It is whether the government will decide, and how quickly, to bring a drug inside that coverage framework.
Why rare disease patients say delay is not just red tape
Rare diseases occupy a special place in health policy because the normal math of the pharmaceutical market often breaks down. Patient populations are small. Clinical trials are usually limited. Long-term evidence can be thin. Prices are often extremely high because drugmakers are trying to recover research and development costs from a tiny number of patients.
Those same characteristics also make delay especially punishing. In many rare diseases, there is no backup treatment, no generic substitute and no meaningful second-best option. Some conditions progress quickly. Others cause irreversible damage if treatment is postponed. In those cases, an administrative delay of several months does not function like a routine paperwork backlog. It can mean the difference between preserving mobility and losing it, between stabilizing a child’s development and watching a narrow treatment window close.
That is why patient groups in South Korea have increasingly framed slow reimbursement decisions not as an inconvenience but as a form of unequal access to care. If a public insurance system exists to protect people from catastrophic medical costs, they argue, then one of the groups most in need of that protection should not be left exposed because standard reimbursement procedures were designed for more common drugs, with larger data sets and easier cost-effectiveness calculations.
For families, the financial stakes can be devastating. Some rare disease therapies can cost the equivalent of thousands or tens of thousands of dollars per month, and in some cases much more. Even in a relatively affluent country such as South Korea, those prices can bankrupt a household, force families to delay treatment or push them into desperate fundraising efforts. The burden is especially acute for parents of children with severe disorders, who may already be dealing with repeated hospital visits, specialist shortages and the long emotional ordeal of getting a correct diagnosis in the first place.
That last point matters. Patients with rare diseases often endure what doctors call a “diagnostic odyssey,” a prolonged search for answers that can stretch for years. In Korea, as elsewhere, families may see multiple specialists before a disorder is identified. If treatment access is then delayed again after diagnosis, families effectively face two separate waiting periods: one to learn what is wrong, and another to learn whether they can actually get the medicine.
What the proposed 100-day system would change
On the surface, the proposal sounds simple: decide faster. But the real significance lies less in the number 100 than in what it implies about the standards Korea might use to judge rare disease treatments.
Under traditional reimbursement models, health authorities often rely on cost-effectiveness analysis, comparative evidence and negotiated pricing. That framework works more smoothly for common conditions, where there are large studies and often multiple available therapies. Rare disease drugs are different. Patient groups are tiny by definition, and the evidence base is frequently limited. That makes it harder to fit these medicines into the same reimbursement template used for diabetes drugs, blood pressure pills or cholesterol treatments.
The policy conversation in Seoul reflects growing recognition that rare disease drugs may require a separate track with different decision criteria. Instead of demanding the same depth of evidence expected for mass-market medicines, the government could place greater weight on clinical urgency, lack of alternatives and broader social value. In other words, Korea may be moving toward a model that says uncertainty should be managed, not used automatically as a reason to delay.
That would be a notable philosophical shift. Rather than forcing every rare disease treatment through a relatively standardized and often slow process, a new framework could identify drugs that are rare, medically essential and effectively irreplaceable, then move them more quickly into reimbursed use, potentially with conditions attached.
Those conditions matter. Fast-tracking a drug would not necessarily mean granting unrestricted coverage. Officials could still limit use to certain hospitals, require tighter prescribing criteria, collect follow-up data from patients or condition reimbursement on future evidence. This type of approach, sometimes called conditional coverage, is increasingly familiar in many health systems trying to balance urgent access with incomplete data.
In the American context, readers might think of it as a compromise between immediate unrestricted approval and yearslong procedural delay. Patients gain a faster route to treatment, but the government retains tools to revisit the decision if real-world outcomes fall short, if costs balloon or if evidence changes.
The bigger question: Should the state buy drugs families now import on their own?
If the fast-track reimbursement proposal is one major part of the debate, the other is even more striking: whether the South Korean government should directly purchase and supply some medicines from abroad when patients cannot reliably access them through the domestic market.
This idea is tied to the practice often referred to in Korea as “direct purchase,” a term commonly used when consumers order products from overseas themselves. Americans may associate that concept with shopping for cheaper electronics, sneakers or skin care online. In the medical context, however, it takes on a much more serious meaning.
For some Korean families, direct purchase has meant personally searching for hard-to-find drugs overseas, figuring out which foreign supplier is trustworthy, navigating import rules, monitoring shipping delays and worrying whether temperature-sensitive medicines were stored properly during transit. In effect, families confronting life-threatening illness have sometimes had to become amateur international procurement specialists.
For parents of medically fragile children or for adults with severe progressive disease, that burden can amount to a parallel health care system built on anxiety and improvisation. Even when direct purchase works, it can be slow, expensive and uncertain. When it fails, the consequences are obvious.
A public procurement model would shift that burden onto the state. If Korea were to adopt such a system, the government could potentially negotiate better prices, verify quality more systematically and create a more stable supply chain for drugs that fall outside normal domestic approval and distribution channels. It would also make a broader statement about the role of government: that access to certain essential medicines should not depend on how resourceful, internet-savvy or internationally connected a family happens to be.
That is a major step for any health system. It would mean the state is not only reimbursing care after a medicine is approved and marketed, but in some cases stepping directly into the purchasing and supply chain for hard-to-access drugs. In policy terms, that expands public responsibility from insurance coverage into procurement logistics, quality assurance and distribution management.
The money problem: Faster access is easier to promise than to fund
As compelling as the patient stories are, the main hesitation inside government is predictable: cost.
Rare disease treatments are expensive almost everywhere, and South Korea is no exception. Even if the number of patients is small, the price per treatment can be so high that a single drug has an outsized impact on insurance spending. That puts policymakers in a bind. Move too slowly, and they are accused — often justifiably — of letting bureaucracy stand between patients and lifesaving care. Move too quickly, and they risk weakening the government’s negotiating leverage with pharmaceutical companies or locking the public insurance system into high-cost commitments based on limited data.
Officials also have reason to worry about incentives. If drugmakers conclude that a fast-track Korean system means the government will more readily accept very high prices, companies may enter negotiations with more aggressive expectations from the start. In that scenario, speed could inadvertently become shorthand for price tolerance.
That is why the Korean debate is not just about shortening timelines. It is also about building financial guardrails. Among the options being discussed are expanded risk-sharing agreements, performance-based payment models, post-listing price adjustments and re-evaluation after a set period. These mechanisms aim to strike a balance: let patients in sooner, but preserve the government’s ability to revisit cost and value once more real-world evidence becomes available.
That logic has parallels in the United States and Europe, where payers and governments are increasingly experimenting with outcomes-based contracts for ultra-expensive therapies. The challenge, in Korea as elsewhere, is that those systems require strong administrative capacity. It is not enough to approve a drug quickly. Authorities also need patient registries, data collection systems, prescribing oversight and the ability to track actual outcomes over time.
Without that infrastructure, a 100-day system could turn into a rushed system rather than a smart one. And if Korea moves forward with direct government purchasing of overseas medicines, the complexity increases further. Officials would need clear rules on legal liability, product verification, procurement standards, budget authority and supply monitoring for drugs that may not fit neatly into existing domestic approval pathways.
In short, speeding up access may be the politically popular part. Building the bureaucracy that can support faster access is the less visible, but probably more important, challenge.
What this means for drugmakers, hospitals and the future of Korean health policy
Pharmaceutical companies have reason to see opportunity in the current debate. Korea is a wealthy, medically sophisticated market, and a more predictable fast-track path for rare disease drugs could make the country more attractive for launching new therapies. For global drugmakers, one longstanding frustration has been uncertainty — not just whether reimbursement will happen, but when. A formalized rapid-review pathway could help reduce that uncertainty.
At the same time, the policy would likely come with tighter expectations. If the Korean government expands public support for rare disease drugs, it may also demand more from industry in return: stronger supply commitments, more price transparency, refunds or rebates if outcomes disappoint, and clearer post-marketing evidence obligations. In that sense, the debate is not simply about giving drugmakers an easier route into the market. It is also about imposing a more explicit public-interest framework on therapies whose pricing and supply can profoundly affect vulnerable patients.
Hospitals and physicians are watching closely, too. Faster reimbursement can help clinicians start treatment earlier and plan care with less uncertainty, but it can also come with new restrictions. Some drugs may be limited to designated centers with relevant expertise. Doctors may need to comply with stricter documentation rules or enroll patients in follow-up monitoring systems. For families, that could mean quicker access overall but also more structured oversight.
What makes this moment significant is that South Korea appears to be moving from an ad hoc model to a structural one. In the past, rare disease drug access often turned into case-by-case public pressure campaigns, with patient groups fighting individual battles over specific medicines. The current debate points toward something broader: a standing policy framework for drugs that are rare, essential and difficult to substitute.
That shift is important well beyond Korea. Across advanced health systems, governments are confronting the same problem. Precision medicine is producing more narrowly targeted treatments, often for smaller patient groups, at higher prices. Traditional reimbursement systems were not built for that reality. Korea’s answer — if it adopts one — may offer a useful case study in how a universal health system can adapt to an era of expensive, evidence-limited but potentially life-changing therapies.
A test of what universal coverage really means
For Americans, South Korea is often held up as an example of efficient universal health coverage: broad enrollment, relatively low administrative complexity and strong health outcomes. But the current rare disease debate is a reminder that universal coverage is not a finished achievement. It is an ongoing argument over what obligations the state has when medicine becomes more specialized, more expensive and less compatible with one-size-fits-all rules.
In that sense, the 100-day proposal is about more than speed. It is about whether a country can redesign its institutions to recognize that some forms of suffering do not fit neatly into standard reimbursement formulas. It is also about whether governments should intervene more aggressively when market incentives leave patients stranded — not just with high bills, but with no reliable route to treatment at all.
That makes the question in Seoul one that would sound familiar in Washington, London or Ottawa: How much uncertainty should the public absorb in order to get desperately ill patients help sooner? And how much public money, administrative effort and political will should be committed to people whose conditions are rare, but whose needs are urgent?
South Korea has not fully answered those questions yet. The details of any eventual policy will matter enormously, especially on pricing, oversight and implementation. A rushed system could create new distortions. A carefully designed one could become a model for how to handle rare disease access in a more humane and realistic way.
What is already clear is that the country’s debate has moved beyond a narrow dispute over reimbursement timelines. It now touches on something bigger: whether the government’s duty ends at evaluating drugs under existing rules, or extends to building an active public safety net for patients who are too few in number to command a normal market — and too sick to wait for bureaucracy to catch up.
For families living with rare disease, that distinction is not abstract. It is the difference between hoping a system eventually works and knowing the system has been designed with them in mind from the start.
0 Comments